Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)
This trial aims to assess efficacy and safety of durvalumab combined with chemoradiotherapy for limited stage small cell lung cancer.
Trial Details
- NCT ID
- NCT06371482
- Phase
- PHASE2
- Sponsor
- Hebei Medical University Fourth Hospital
- Status
- RECRUITING
- Cancer Type
- Lung Cancer
- Interventions
- Durvalumab
- Chemotherapy drug of EP regimen
- radiotherapy
- Locations (sample)
- Shijiazhuang, Hebei, China|38.04139,114.47861
Key Eligibility Criteria
- Voluntary participation and written signed informed consent;
- Age 18-75 years old, gender is not limited;
- Histologically or cytologically confirmed limited-stage small cell lung cancer (2009 AJCC/UICC/IASLC lung cancer TNM staging criteria, limited-stag…
- There are immunohistochemical results;
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lung Cancer Trials on Trialify →